Related Experiment Video
Updated: Aug 3, 2026
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone
Veronica Giusti1, Leonardo Fantoni1, Monica Torsello1
1Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
Abstract:
Bone metastases from osteosarcoma occur in only 10% of patients, and related preclinical models are lacking. A patient diagnosed with pelvic osteosarcoma developed a metachronous scapular metastasis and was treated with multi-agent chemotherapy and surgery. Patient-derived tissue fragments (PDTFs) were obtained from leftover material after diagnosis and biobanking. PDTFs were grown on chick chorioallantoic membrane, establishing an in vivo-like predictive model. Additionally, we obtained a patient-derived cell culture, OS-MET-R-092, which has been maintained in vitro for nearly one year. OS-MET-R-092 cells were authenticated based on short tandem repeats and on their morphology when grown on commercial 3D scaffolds. Using U-2 OS and SaOS-2 as controls, we characterized growth, clonogenic potential, ability to form spheroids, migration, osteogenic differentiation, and expression of related genes. OS-MET-R-092 cells showed a low proliferation rate, impaired differentiation potential, and migratory abilities comparable to SaOS-2, while expressing higher levels of some MMPs and CD44. Functionally, OS-MET-R-092 cells demonstrated a resistant phenotype to doxorubicin, cisplatin, gemcitabine, and docetaxel, corroborated by higher expression of chemo-resistance-related genes. Collectively, OS-MET-R-092 represents a valuable tool for studying bone metastasis from osteosarcoma across various experimental settings and serves as the foundational building block for composite and translatable 3D models.
Insights
A novel patient-derived cell line, OS-MET-R-092, was developed from osteosarcoma bone metastasis. This model exhibits drug resistance and aids in studying osteosarcoma metastasis and developing 3D models.
Area of Science:
- Oncology
- Cancer Biology
- Translational Research
Background:
- Osteosarcoma bone metastases are rare (10%) with limited preclinical models.
- A patient with pelvic osteosarcoma developed scapular metastasis, providing tissue for research.
Purpose of the Study:
- To establish and characterize a patient-derived preclinical model for osteosarcoma bone metastasis.
- To evaluate the OS-MET-R-092 cell line's characteristics, including drug resistance and gene expression.
Main Methods:
- Patient-derived tissue fragments (PDTFs) were used to create an in vivo chick chorioallantoic membrane model.
- A patient-derived cell culture (OS-MET-R-092) was established and maintained in vitro.
- Cells were characterized for growth, migration, differentiation, gene expression, and drug resistance, using U-2 OS and SaOS-2 as controls.
Main Results:
- The OS-MET-R-092 cell line demonstrated low proliferation, impaired differentiation, and moderate migration.
- Cells exhibited resistance to multiple chemotherapeutic agents (doxorubicin, cisplatin, gemcitabine, docetaxel).
- Higher expression of matrix metalloproteinases (MMPs) and CD44 was observed in OS-MET-R-092 cells.
Conclusions:
- OS-MET-R-092 is a valuable, authenticated preclinical model for studying osteosarcoma bone metastasis.
- This model facilitates research into chemoresistance mechanisms and the development of advanced 3D models.
- The model holds potential for preclinical drug screening and therapeutic strategy development.
